Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

In this study, we present the first integration of the spin-unrestricted similarity-transformed equation-of-motion coupled cluster method (CVS-USTEOM-CCSD) for core-excited and core-ionized states ...

Prior to joining Vertex, Mr. Smith served as the Chief Executive Officer of Philadelphia Energy Solutions Inc. and the President of Western Refining, Inc. The Company is pleased to welcome a new ...

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

In a mesmerising blend of art and mathematics, a research student from University College London (UCL) has recently gained widespread attention for creating intricate images solely through ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes. In a court filing on ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

Jan 13 (Reuters) - Goldman Sachs (GS.N), opens new tab on Monday announced plans to combine key business segments under a single unit named 'Capital Solutions Group,' to grow in private credit ...